Navigation Links
Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
Date:4/23/2008

stics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.

We leverage our preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits us to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Carrington Completes $8 Million Financing
8. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
9. New Brunswick Scientific Completes Merger Transaction with Eppendorf
10. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
11. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... FL (PRWEB) May 22, 2013 A recent ... of probiotics on athletes to find that those who took ... longer. The results from the study showed that in extreme ... Action, known for their adult acne treatment explains ... and how it may help their skin condition. , ...
(Date:5/22/2013)... Mass. , May 22, 2013  Moderna Therapeutics, ... new treatment modality to enable the in vivo ... John Reynders will join Moderna in ... Reynders is a proven leader in the ... of drug development, from discovery to translation, clinical operations ...
(Date:5/21/2013)... BEACH, Fla. , May 21, 2013 /PRNewswire/ ... FCN ), the global business advisory ... their enterprise value (the "Company"), announced that it ... personnel that were formerly included within the Corporate ... Litigation Consulting segment to form a single integrated ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3
... Singapore investigators to coordinate 700 patient trial of ... of head and neck cancer,MISSISSAUGA, ON, Jan. 5 ... TSX:YM, AIM:YMBA), an oncology company that identifies, develops ... announced that the National Cancer Centre of Singapore ...
... Penn Allegheny,Health System and The Western Pennsylvania Hospital announced ... Jones, MD, FACS,and Roger R. Barrette, MD, formerly of ... Drs. Jones and Barrette will direct the ... for the treatment of burn injuries. West Penn,is ...
... the backdrop of a flagging,economy, bailouts, and bleak ... with a future as bright as New Year,s ... market the Embozene(TM),Color-Advanced Microspheres embolization platform for the ... of blood vessels in many,locations) and arteriovenous malformations ...
Cached Biology Technology:YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 2YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 3YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 4West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 2West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 3First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 2First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 3First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 4
(Date:5/21/2013)... , Where? Copenhagen, Denmark: Bella Center Congress ... , Why? An annual meeting ... developments, manufacturing and installation, drawing on leading experiences from ... edition from a record of more than 900 abstracts ... plenary and oral presentations, more than 460 visual presentation, ...
(Date:5/21/2013)... May 21, 2013 Royal Philips Electronics (NYSE: ... world,s first portable ultrasound with Philips, industry leading Live ... The CX50 xMATRIX with available Live 3D TEE and ... at the EuroPCR, official meeting for the European ... Since its launch in 2012, Philips CX50 xMATRIX ...
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... FASEB Journal provide more evidence that if we ... improve. According to MIT scientists, dietary nutrients found in ... eggs increase brain synapses and improve cognitive abilities. ... animals, respond to this kind of treatment by making ...
... State University faculty member who uses computational techniques ... is attracting worldwide attention from other researchers. ... and biomedical engineering at the Florida A&M University-Florida ... computers to determine how substances known as recombinant ...
... alarmed by the dramatic decline of at least 30 percent ... Nepal, once a refuge that boasted among the highest densities ... survey of April 2008 showed a population of between 6-14 ... Government of Nepal made a low-key announcement on July 1 ...
Cached Biology News:FSU researcher using computers to hone cancer-fighting strategies 2Tigers disappear from Himalayan refuge 2
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
...
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
Biology Products: